United Kingdom real-world experience of sotorasib in KRAS G12C mutant non-small cell lung cancer: A British thoracic oncology group review
Authors
Julve, M.Kennedy, O.
Lindsay, Colin R
Walters-Davies, R.
Button, M. R.
Steele, N.
McGeogh, A.
Georgiou, A.
Goranov, B.
Farrugia, D.
Gorf, L.
Remer, M.
Shah, R.
Baijal, S.
Gennatas, S.
Geldart, T.
Daniels, E.
Watts, L.
Greystoke, A.
Newsom-Davis, T.
Affiliation
Oncology Department, Chelsea and Westminster Hospital - NHS Trust, LondonIssue Date
2022
Metadata
Show full item recordCitation
Julve M, Kennedy O, Lindsay C, Walters-Davies R, Button MR, Steele N, et al. United Kingdom real-world experience of sotorasib in KRAS G12C mutant non-small cell lung cancer: A British thoracic oncology group review. Annals of Oncology. 2022 Sep;33(7):S1061-S2. PubMed PMID: WOS:000866211601380.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.07.1241Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.07.1241Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.07.1241